Member of the Board since 2013 and Vice Chairman since June 2018.
Steen Riisgaard was born in 1951 and is a Danish national. He received an MSc in Microbiology from the University of Copenhagen. He began his career as a research fellow at Statens Serum Institute (SSI) and a research microbiologist at Foss Electric, Denmark.
Steen Riisgaard has over 34 years of experience in Industrial Biotechnology. He joined the Novo Nordisk Enzymes Division (now Novozymes A/S) Research & Development team in 1979. In 1982, he moved to Tokyo to start up a new enzymes research and development unit in the Novo Nordisk subsidiary, Novo Industry Japan Ltd. He returned to Denmark in 1985 and held a number of different positions in the company until 1989 when he was promoted to Corporate Executive Vice President of the Enzymes Business. In 2000 Steen Riisgaard became the President and CEO of Novozymes A/S, from the demerger from Novo Nordisk A/S in 2000, and served in that position until April 2013.
In addition to the Novo Holdings A/S Board, Steen Riisgaard currently serves as Chairman of the Board of COWI Holding A/S and New Xellia Group A/S. Furthermore, he is Vice Chairman of the Board of the Villum Foundation, Board member of the Novo Nordisk Foundation based in Denmark, Board member and Substitute for Aarhus University in Denmark and Board member in Corbion N.V. in the Netherlands.